Unclaimed brand
BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. A University of British Columbia (“UBC”) spin-off, BirchBioMed holds the exclusive, worldwide pharmaceutical license from UBC for two medical therapeutic technologies that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases. Initially funded by key strategic donors and government bodies, including the Canadian Institute of Health Research and the Natural Sciences and Engineering Research Council of Canada (the Canadian counterpart of the U.S. National Institutes of Health), BirchBioMed's licensed technology has secured more than $6 million in government and association grants, coupled with additional university resources. It is also the first technology that UBC has advanced from discovery through Phase I clinical trials with support strictly from government/private donations.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#FCB900
Selective Yellow
252, 185, 0
44, 100, 49
0, 27, 100, 1
#FFF5CB
Barley White
255, 245, 203
48, 100, 90
0, 4, 20, 0
#32373C
Outer Space
50, 55, 60
210, 9, 22
17, 8, 0, 76
BirchBioMed is a clinical stage pharmaceutical company that is dedicated to developing innovative treatments for scarring (fibrosis), related skin disorders, certain autoimmune diseases, and organ fibrosis. As a spin-off of the University of British Columbia (UBC), BirchBioMed holds the exclusive worldwide pharmaceutical license for two groundbreaking medical therapeutic technologies, FS1/FS2 and AI-001. This remarkable technology has made significant strides in the medical field, having successfully advanced from the discovery stage to Phase 1 clinical trials, with support from government and private donations.
BirchBioMed has received over $6 million in grants from prestigious government research institutions such as the Canadian Institute of Health Research and the National Science and Engineering Research Counsel. Heading its research and development is a team of experts committed to strategic drug development, therapeutic options, and market access. The company's Chief Medical Officer, Dr.
Carlos Roberto Camozzi, brings extensive experience in leading regulatory interactions and obtaining approvals from renowned organizations such as the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
With its focus on advancing medical breakthroughs and improving patient outcomes, BirchBioMed is at the forefront of revolutionizing the treatment of fibrosis and autoimmune diseases
Company type
Privately Held
Year founded
2015
Company size
11-50 employees
How do I download the BirchBioMed Inc. logo?
The BirchBioMed Inc. logo comes in two versions: a white logo and an icon. Download as transparent PNG or JPEG.
What are BirchBioMed Inc.'s brand colors?
The BirchBioMed Inc. color palette uses the hex codes #FCB900, #FFF5CB and #32373C.
The BirchBioMed Inc. name, logos and brand assets are trademarks of BirchBioMed Inc. and its affiliates. Brandfetch isn't affiliated with or endorsed by BirchBioMed Inc.. Their use is subject to BirchBioMed Inc.'s brand guidelines.
